Gozetotide

CHEMBL3578202 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
947.0 g/mol
LogP
-3.9
Phase
4

A targeted radiopharmaceutical agent used in the diagnosis and treatment of certain cancers, including prostate and breast cancer. It binds to specific proteins overexpressed on cancer cells, allowing for precise imaging or delivery of radiation.

Molekularmasse

947,0000 g/mol

LogP

-3,90

TPSA

370,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Wirkmechanismus

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1

InChI

InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1

Molecular Formula

C44H62N6O17

HBD / HBA

12 / 19

Rotierbare Bindungen

35

Schwere Atome

67

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A targeted radiopharmaceutical agent used in the diagnosis and treatment of certain cancers, including prostate and breast cancer. It binds to specific proteins overexpressed on cancer cells, allowing for precise imaging or delivery of radiation.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Gozetotide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3578202. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60143283. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.